Dambkowski Carl 4

What Happened

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), exercised options to acquire 4,125 shares at $22.86 per share (cost $94,298) on February 4, 2026. On the same date he sold a total of 5,500 shares in open-market transactions for aggregate gross proceeds of about $361,860 (sales at weighted average prices ranging from $64.24 to $68.98 per share across multiple trades). The filing also shows a disposition of 4,125 shares at $0 (derivative entry) related to the exercise.
• These actions include both an option exercise (M) and multiple sales (S). Sales are routine insider disposition activity; the exercise is an acquisition of shares by exercising a derivative right.

Key Details

• Transaction date: February 4, 2026 (Form filed same day).
• Option exercise: 4,125 shares acquired at $22.86 each = $94,298.
• Open-market sales: 5,500 shares sold in multiple trades for total proceeds ≈ $361,860 (individual blocks: 2,481 @ ~$64.88; 1,420 @ ~$65.83; 1,299 @ ~$66.85; 100 @ ~$67.88; 200 @ ~$68.94; reported as weighted averages with ranges in footnotes).
• Derivative disposition: 4,125 shares reported disposed at $0 (listed as M/derivative in filing).
• Footnotes: F1 — sales executed under a Rule 10b5-1 trading plan adopted Sept 22, 2025. F2–F6 — reported sale prices are weighted averages with per-trade price ranges (ranges provided in filing). F7 — the option pool referenced covers 175,345 shares that vest monthly through Dec 18, 2027.
• Shares owned after the transactions: not specified in the summary information provided in your request (refer to the Form 4 for post-transaction beneficial ownership).
• Filing timeliness: filed for the same date as the transactions (no late filing indicated).

Context

• The filing shows an option exercise plus contemporaneous sales. The separate line showing a disposition of 4,125 shares at $0 commonly reflects a net share settlement, surrender, or similar administrative action connected to the exercise (e.g., to cover exercise cost or taxes); check the full Form 4 footnotes for issuer-specific details.
• Sales executed under a 10b5-1 plan indicate pre-scheduled transactions — this is routine and not direct evidence of sentiment. Purchases (exercises) can be meaningful, but in this case many shares were sold the same day or reported under plan-driven sales.